Our products
Innovation
Genexpath's core business is the development of tumor classification tests. These solutions are designed to meet the needs of professionals involved in patient diagnosis and treatment.
The tests are based on an innovative technique which has been the subject of several publications in high-impact scientific journals, and has been the subject of four patent applications. The technique has already been tried and tested.
These tests are performed on tumor RNA biopsied from the patient. The innovation lies in the fact that the quantity of RNA required is very small, and that in the case of sarcoma, a less invasive needle biopsy is sufficient to detect fusion transcripts.
Genexpath kits allow much faster and much cheaper analysis than more traditional methods.
Classification tests
Genexpath currently markets 3 tumor classification tests: LymphoSign test, SarcomaFusion test and LymphoTranscript. These solutions combine an in vitro test (LD-RT-PCR) with bioinformatics analysis after NGS sequencing.
Our products are optimized for difficult samples or small quantities. The simple and fast protocol facilitates the deployment of the technique within the various departments. It does not require any specific hardware. Conventional laboratory equipment is sufficient as well as an NGS sequencer.
These tests can be sequenced simultaneously with other libraries, and require only 100,000 reads per sample. This is a great advantage for laboratories, and a significant cost saving. There's no need to wait until you have enough samples to start sequencing, or to monopolize the sequencer for these tests alone.
After sequencing, our RT-MIS software, combined with artificial intelligence for the classification of non-Hodgkin lymphomas, facilitates the interpretation of the results.
RT-MIS is quick and easy to use, with no local installation required. The results provided are extremely comprehensive.
These tests are the result of research carried out by Inserm Unit 1245 at the Henri Becquerel Centre in Rouen, with which Genexpath works closely. They are now available to all hospitals throughout the world
Finally, tests have shown that this solution can identify cases that remain undetected by conventional techniques.
GenerateReports software
Genexpath also markets the software GenerateReports qui permet l’analyse et l’interprétation des résultats de séquençage à haut-débit.
GenerateReports supports a wide variety of raw data and incorporates the latest algorithms published in the literature for variant detection.
GenerateReport est économique et s’adapte parfaitement aux projets de recherche muticentriques que nous sommes très fiers de pouvoir accompagner.
In the future, Genexpath aims to develop and/or industrialize other classification tests in order to facilitate the work of professionals. Our ambition is also to once again make the work of researchers available to as many people as possible.
Testimonials
"I'm a clinical hematologist at the Henri Becquerel Center in Rouen, and I'm also involved in translational research at INSERM Unit U1245 in Professor JARDIN's team. I have carried out several research projects on the molecular characterization of lymphomas, using RT-MLPA with the LymphoSign signature to study the gene expression profile of lymphomas.
At the Centre Henri Becquerel, the LymphoSign technique is available for routine use as an aid to lymphoma diagnosis, and is proving invaluable for the accurate classification of lymphomas, as well as helping the pathologist to diagnose difficult cases, which are not so rare in practice.
I'm particularly interested in primary B lymphomas of the mediastinum (PMBL), which are a unique and rare entity of aggressive mature B-cell lymphoma, preferentially affecting young patients with a female predominance. Diagnosis of these lymphomas is difficult, and the LymphoSign technique is in my view a very useful companion test for accurately identifying and diagnosing these cases, with strong clinical consequences since the treatment and prognosis of these lymphomas is quite different from other aggressive B-cell lymphomas."
Dr Vincent CAMUS , clinical hematologist at the Centre Henri Becquerel in Rouen, France
LymphoTranscript
The genetics of peripheral T-cell lymphoma (PTCL) are complex, encompassing several recurrent fusion transcripts discovered in recent ...
Custom Panels
The solution Custom Panels from Genexpath allows you to assess the mRNA expression level of 10 to 100 markers of interest of your choice.
LymphoSign test
The LymphoSign test developed by Genexpath offers precise measurement of the expression signature of over 130 genes of interest...
GenerateReports
While new DNA sequencing technologies make it possible to characterize tumors ever more accurately, they also generate large volumes of data that must be interpreted...
SarcomaFusion test
Fusion transcripts are present/found in around 1/3 of soft tissue tumors and to date, the literature has described more than ...